Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 189
- Press Release
- Press Release PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data
- PharmAbcine
- 9 Nov 2023
- Views2288
- 0
- 188
- Press Release
- Press Release PharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDAยฎ (pembrolizumab)
- PharmAbcine
- 18 Sep 2023
- Views2372
- 0
- 187
- Press Release
- Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
- PharmAbcine
- 24 May 2023
- Views3160
- 0
- 186
- CEO Story
- CEO Story IMAPAC Singapore Biopharma Awards 2023
- PharmAbcine
- 24 Mar 2023
- Views2578
- 0
- 185
- CEO Story
- CEO Story Clinical Trials Festival Asia 2023 - IMAPAC
- PharmAbcine
- 20 Jan 2023
- Views4277
- 0
- 184
- CEO Story
- CEO Story Dr. Yoo to participate in the 41th Annual J.P. Morgan Healthcare Conference
- PharmAbcine
- 27 Dec 2022
- Views2789
- 0
- 183
- Press Release
- Press Release PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDAยฎ (pembrolizumab)
- PharmAbcine
- 13 Dec 2022
- Views3150
- 0
- 182
- CEO Story
- CEO Story PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcaseโข 2023 and JPM@BIO
- PharmAbcine
- 9 Dec 2022
- Views2312
- 0
- 181
- Press Release
- Press Release PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcaseโข 2023 during JPM Week
- PharmAbcine
- 9 Dec 2022
- Views1999
- 0
- 180
- CEO Story
- CEO Story Jefferies 2022 London Healthcare Conference
- PharmAbcine
- 25 Oct 2022
- Views1727
- 0